Clinical Trials Directory

Trials / Completed

CompletedNCT03943888

Pharmacokinetic-pharmacodynamic Analysis of Sugammadex in Children

Pharmacokinetic-pharmacodynamic Analysis of Reversal of Rocuronium-induced Neuromuscular Blockade by Sugammadex in Children

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
40 (actual)
Sponsor
Seoul National University Hospital · Academic / Other
Sex
All
Age
2 Years – 17 Years
Healthy volunteers
Not accepted

Summary

This study administers sugammadex sodium to pediatric patients under general anesthesia with rocuronium. Pharmacokinetic and pharmacodynamic analysis are performed based on plasma concentration of sugammadex sodium and monitoring of neuromuscular blockade.

Detailed description

This study enrolls pediatric patients undergoing surgery under general anesthesia with need for early reversal of neuromuscular blockade, aged between 2 and 18 years old. After routine anesthetic induction with 1% propofol and 0.6mg/kg of rocuronium, maintenance of anesthesia with total intravenous anesthesia is commenced. 15 minutes after rocuronium administration, 2 or 4 or 8mg/kg of sugammadex sodium or conventional neuromuscular reversal agent is administered according to randomization table. For neuromuscular monitoring, train-of-four (TOF) count and T4/T1 ratio are monitored, with recording of the time to recovery of the T4/T1 ratio to 0.7, 0.8 and 0.9. For pharmacokinetic analysis, patient blood sample is obtained before / 2 min after rocuronium administration, before / 2min / 5min / 15min / 60min / 120min / 240min / 480min after sugammadex administration. Plasma concentration of rocuronium and sugammadex sodium are analyzed via high-performance liquid chromatography with mass spectrometric detection.

Conditions

Interventions

TypeNameDescription
DRUGSugammadex Injection 2mg/kgIntravenous injection of 2mg/kg of sugammadex sodium 15 minutes after rocuronium administration
DRUGSugammadex Injection 4mg/kgIntravenous injection of 4mg/kg of sugammadex sodium 15 minutes after rocuronium administration
DRUGSugammadex Injection 8mg/kgIntravenous injection of 8mg/kg of sugammadex sodium 15 minutes after rocuronium administration
DRUGNeuromuscular reversal agent injectionIntravenous injection of 0.02mg/kg of atropine and 0.03mg/kg of neostigmine

Timeline

Start date
2019-08-12
Primary completion
2020-02-20
Completion
2020-02-20
First posted
2019-05-09
Last updated
2022-11-14
Results posted
2022-11-14

Locations

1 site across 1 country: South Korea

Regulatory

Source: ClinicalTrials.gov record NCT03943888. Inclusion in this directory is not an endorsement.